|
| Press Releases |
|
 |
|
| Friday, August 6, 2021 |
|
|
エーザイ、第37回企業広報賞「企業広報大賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、一般社団法人日本経済団体連合会（東京都）の関連団体である一般財団法人経済広報センター（東京都、会長：十倉雅和）が主催する第37回企業広報賞において、「企業広報大賞」を受賞しましたのでお知らせします。 more info >> |
|
| Thursday, August 5, 2021 |
|
|
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards |
| Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs, an affiliate of the Japanese Business Federation (Tokyo). more info >> |
|
| Monday, August 2, 2021 |
|
|
Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures |
| Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) has obtained two additional approvals as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for pediatric indication for partial onset seizures in patients with epilepsy 4 years of age and older" in China from the National Medical Products Administration. more info >> |
|
|
エーザイ、抗てんかん剤「フィコンパ(R)」が中国において部分てんかんの単剤療法および小児適応に係る承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、自社創製の抗てんかん剤「フィコンパ(R)」（一般名：ペランパネル）について、中国国家薬品監督管理局より、「てんかんの部分発作に対する単剤療法」および「4 歳以上の小児てんかんの部分発作に対する併用・単剤療法」の 2 つの追加適応の承認を取得しましたのでお知らせします。 more info >> |
|
| Friday, July 30, 2021 |
|
|
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401) |
| Eisai Co., Ltd. and Biogen Inc. today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) -- granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021. more info >> |
|
|
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の対象銘柄に20年連続で選定 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、社会的責任投資の代表的な指数である「FTSE4Good Index Series」の構成銘柄に、2002年以来20年連続で選定されましたのでお知らせします。 more info >> |
|
|
エーザイとバイオジェン、アルツハイマー病の初めてのリアルワールド観察臨床第IV相試験となるADUHELM ICARE AD-USの試験デザインをアルツハイマー病協会国際会議2021において発表 |
| more info >> |
|
|
エーザイとバイオジェン、Lecanemab（BAN2401）の臨床効果についてアルツハイマー病協会国際会議2021（AAIC2021）のLate Breakingとして発表 |
| Lecanemabの臨床第II相POC試験後のOpen Label Extension試験における18カ月投与の臨床効果に関する予備解析結果をAAIC2021において発表 more info >> |
|
|
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021 |
| Biogen and Eisai Co., Ltd. today announced that Biogen led a late-breaking presentation on the design of the first real-world observational Phase 4 study in Alzheimer's disease called ICARE AD-US, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
| Thursday, July 29, 2021 |
|
|
Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 20th consecutive year since its initial inclusion in 2002. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Annature Launches 21 CFR Part 11 Compliant Digital Signatures to Support FDA-Regulated Organisations
Feb 5, 2026 13:00 HKT/SGT
|
|
|
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States
Feb 5, 2026 12:54 HKT/SGT
|
|
|
Goldenstone Acquisition Limited (Ticker: GDST) Announces Intent to Merge with ESG Packaging Innovator Deluxe Technology Group, Targeting 2026 NASDAQ Listing
Feb 5, 2026 12:53 HKT/SGT
|
|
|
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 5, 2026 11:55: JST
|
|
|
SuperX Strengthens Japan Presence to Explore AI Data Center Projects with Local Partners
Feb 5, 2026 11:00 HKT/SGT
|
|
|
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 5, 2026 10:55 HKT/SGT
|
|
|
雲頂新耀宣佈與麥科奧特達成MT1013獨家商業化許可協議
Feb 5, 2026 10:55 HKT/SGT
|
|
|
云顶新耀宣布与麦科奥特达成MT1013独家商业化许可协议
Feb 5, 2026 10:55 HKT/SGT
|
|
|
Hitachi significantly expands exhibits at the "Hitachi Building Solutions Lab", a research facility for collaborative creation with customers
Feb 5, 2026 11:48 JST
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES, 체외 진단약 등 각종 검사 키트 위탁 제조를 위한 토탈 솔루션 체계 구축
Feb 5, 2026 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES在接受委託製造體外診斷試劑等各種檢驗套組中 確立綜合式的解決方案體制
Feb 5, 2026 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES在体外诊断试剂等的各种检测试剂盒的受托制造中 确立全面解决方案体制
Feb 5, 2026 10:00 HKT/SGT
|
|
|
愛格法醫療榮獲2026年KLAS(R)評鑑美國三大企業影像領域最佳供應商殊榮
Feb 5, 2026 05:00 HKT/SGT
|
|
|
爱克发医疗荣膺2026年KLAS(R)美国三大企业影像领域最佳供应商
Feb 5, 2026 05:00 HKT/SGT
|
|
|
Goldenstone Acquisition Limited (Ticker: GDST) Announces Intent to Merge with ESG Packaging Innovator Deluxe Technology Group, Targeting 2026 NASDAQ Listing
Feb 4, 2026 23:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
